Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction - Archive ouverte HAL Access content directly
Journal Articles Transfusion Year : 2022

Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction

(1) , (1) , , , (1) , (2) , (3) , (3) , , , (1)
1
2
3

Abstract

Background: Plasmodium falciparum is the parasite responsible for most malaria cases globally. The risk of transfusion-transmitted malaria (TTM) is mitigated by donor deferrals and blood screening strategies, which adversely impact blood availability. Previous studies showed robust inactivation of P. falciparum using nucleic acid-targeting pathogen reduction technologies (PRT) for the treatment of plasma and platelet components or whole blood (WB). The efficacy of the amustalineglutathione (GSH) PRT to inactivate P. falciparum is here evaluated in red blood cells (RBC), as well the impact of PRT on parasite loads, stages, and strains. Study Design and Methods: RBC units resuspended in AS-1 or AS-5 additive solutions were spiked with ring stage-infected RBC and treated with the amustaline-GSH PRT. Parasite loads and viability were measured in samples at the time of contamination, and after treatment, using serial 10-fold dilutions of the samples in RBC cultures maintained for up to 4 weeks. Results: P. falciparum viability assays allow for the detection of very low levels of parasite. Initial parasite titer was >5.2 log 10 /ml in AS-1/5 RBC. No infectious parasites were detected in amustaline-GSH-treated samples after 4 weeks of culture. Amustaline-GSH inactivated high parasite loads regardless of parasite stages and strains. Amustaline readily penetrates the parasite, irreversibly blocks development, and leads to parasite death and expulsion from RBC. Discussion: Amustaline-GSH PRT demonstrated robust efficacy to inactivate malaria parasites in RBC concentrates. This study completes the portfolio of studies demonstrating the efficacy of nucleic acid-targeting PRTs to mitigate TTM risks as previously reported for platelet concentrates, plasma, and WB. Cissé Sow and Amélie Bouissou are co-first authors.
Fichier principal
Vignette du fichier
2022_Transfusion - Sow - Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and.pdf (1.84 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

mnhn-03650093 , version 1 (24-04-2022)

Identifiers

Cite

Cissé Sow, Amélie Bouissou, Yvette Girard, Gurvani Singh, Lotfi Bounaadja, et al.. Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction. Transfusion, In press, ⟨10.1111/trf.16867⟩. ⟨mnhn-03650093⟩

Collections

MNHN CNRS
6 View
7 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More